FSHD Europe
The united European Voice for People with FSHD

FSHD Europe unites and amplifies the voice of FSHD patients across Europe, raising awareness and interest among all stakeholders, including researchers, clinicians, pharmaceutical companies, regulators, payors, and national patient organizations.

NEW date: FSHD Connect Europe patient meeting 2025

 

FSHD Europe will organize, in collaboration with the FSHD Society, the first FSHD Connect Europe meeting on June 13th – June 15th, 2025, in Amsterdam, The Netherlands. This is a networking meeting for FSHD patients and their families. Attendees will be informed about the latest research, drug development, and clinical trials, as well as managing symptoms and improving quality of life. It is a great opportunity to connect with other patients and families across Europe. More details will follow early 2025 on our website and in our newsletter. We hope to see you there!

Get involved!

Our members are national patient organizations who support FSHD patients or neuromuscular diseases in general.

FSHD European Trial Network (ETN)

In 2021, FSHD Europe established the FSHD European Trial Network (ETN) to support collaboration to reach trial readiness, building on current research on FSHD in Europe.

Nicol Voermans as chair and Pascal Laforet as vice chair; George Padberg and Baziel van Engelen as advisors coordinate this project, initiated by FSHD Europe.

The primary goal of the FSHD European Trial Network is to connect the clinicians involved in care for FSHD in all European countries and increase the trial capacity in Europe allowing more centres to participate in upcoming trials and making new treatments widely accessible to patients.

News & articles

Welcome FSHD Finland to FSHD Europe!

We are excited to announce that FSHD Finland has joined FSHD Europe. Lauri Pirinen and Lora Chun are the patient representatives of FSHD Finland. They did an incredible job in starting their own organization in a very short time. We look forward to a successful collaboration.

Curious about their inspiring story? In a case study, they share how FSHD Finland was established, and it provides valuable insights to encourage other countries to start their own patient organization. 

279th ENMC Workshop 1-3 November 2024

FSHD Europe participated in the 279th ENMC workshop “Classification, clinical care, outcome measures and biomarkers in childhood-onset FSHD: towards standardising clinical care and ensuring clinical trial readiness”. Twenty-seven participants, including clinicians, research experts, patient advocates, and industry representatives, from 14 different countries engaged in this workshop.
FSHD Europe would like to thank the organizers, Dr C. Erasmus (The Netherlands), Prof. K. Mathews (USA), K. de Valle (Australia) and Prof. T. Willis (UK), for the opportunity to present on the FSHD European Trial Network & Market Access. We had very interesting and fruitful discussions on the spectrum of FSHD, the challenges of trials in children, and the most appropriate clinical outcome measures. Gaps of knowledge were defined, and task groups were formed to work on this. Hence, we will continue working together towards clinical trial readiness for children with FSHD.
For more information, please read the lay report which is published on the ENMC website (click here).
Lay reports – ENMC

NEW date: FSHD Connect Europe patient meeting 2025

Save the date: FSHD Connect Europe patient meeting 2025
FSHD Europe will organize, in collaboration with the FSHD Society, the first FSHD Connect Europe meeting on June 13th – June 15th, 2025, in Amsterdam, The Netherlands.

Join Us!

FSHD Europe is the voice of FSHD patients across Europe and by joining you will become part of that bigger and louder voice. We work with clinicians and researchers, regulators, and pharmaceutical companies.

We aim to be open and transparent in our approach and be respectful of cultural differences and the priorities of individual member organisations.